Skip to content

Characterisation of sensor accuracy performance for Continuous Glucose Monitoring (CGM) systems

Characterisation of sensor accuracy performance for CGM systems

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN30194092
Enrollment
4500
Registered
2025-05-28
Start date
2025-05-19
Completion date
Unknown
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes mellitus Nutritional, Metabolic, Endocrine

Interventions

Each study arm will involve the use of CE-marked Continuous Glucose Monitoring (CGM) systems. Adults with Type 1 or Type 2 diabetes will wear between one and three sensors for a period of up to 31 day

Sponsors

Abbott Diabetes Care Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged at least 18 years old. 2. Have type 1 or type 2 diabetes. 3. Is willing to provide a minimum of 4 and no more than 12 capillary fingerprick blood samples for each day of sensor wear. 4. Is able to read and understand English. 5. In the investigator’s opinion, the participant is willing to wear the sensor(s), to follow the instructions provided to him/her by the study site and perform all study tasks as specified by the protocol. 6. Agrees to continue using their current method of glucose monitoring for duration of study.

Exclusion criteria

Exclusion criteria: 1. Has participated in the same study event. 2. Is a member of the study staff. 3. Is pregnant, planning to become pregnant within the study event duration, or becomes pregnant during the study. 4. Has known (or suspected) allergy to medical grade adhesive at enrolment. 5. Has a skin abnormality at the application sites. 6. Is currently participating in another clinical study that could affect their glucose management. 7. Has a known concomitant medical condition which, in the opinion of the investigator, could present a risk to the safety or welfare of the participant or study staff. 8. Has a pacemaker or any other neurostimulators. 9. Is unsuitable for participation due to any other cause as determined by the investigator.

Design outcomes

Primary

MeasureTime frame
The proportion of system readings that are within ±20% for glucose levels =70 mg/dL and within ±20 mg/dL for glucose levels <70 mg/dL compared to capillary fingerstick blood glucose (BG) values, over the duration of sensor wear

Secondary

MeasureTime frame
Safety outcomes (AEs/ DIs) will be recorded, over the duration of sensor wear

Countries

England, Scotland, United Kingdom

Contacts

Public ContactPamela Reid
pamela.reid@abbott.com+44 1993 863024

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026